Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101/203 TIL in Advanced Solid Tumors
NCT07294872Phase 1Not yet recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Dec 2026
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of nolgileucel and GC203 in solid tumor (2 arms), sponsored by Juncell Therapeutics. Primary endpoint: Adverse Events at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nolgileucelGC203
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07294872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294872.